Inhibrx, Inc. (INBX)
|Net Income (ttm)||-76.12M|
|Trading Day||May 13|
|Day's Range||15.30 - 16.98|
|52-Week Range||14.27 - 50.97|
Inhibrx Inc (NASDAQ: INBX) has announced results from the dose escalation of the Phase 1 study evaluating INBRX-105 in locally advanced or metastatic solid tumors. INBRX-105 is a precisely engineered mu...
Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalat...
SAN DIEGO, March 12, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the fourth quarter and fi...
SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced to...
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates als... [Read more...]
|IPO Date |
Aug 19, 2020
|Stock Exchange |
|Ticker Symbol |
In 2020, Inhibrx's revenue was $12.89 million, a decrease of -2.44% compared to the previous year's $13.21 million. Losses were -$76.12 million, 48.1% more than in 2019.
According to 4 analysts, the average rating for Inhibrx stock is "Strong Buy." The 12-month stock price forecast is 40.50, which is an increase of 140.78% from the latest price.